Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy ProgramsBusiness Wire • 06/02/22
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid TumorsGlobeNewsWire • 05/18/22
Strength Seen in Immatics (IMTX): Can Its 5.3% Jump Turn into More Strength?Zacks Investment Research • 05/13/22
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid TumorsGlobeNewsWire • 05/10/22
Wall Street Analysts See a 178% Upside in Immatics (IMTX): Can the Stock Really Move This High?Zacks Investment Research • 04/15/22
Immatics Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/16/21
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAMEGlobeNewsWire • 11/09/21
Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer's 36th Annual MeetingGlobeNewsWire • 11/01/21
Immatics Announces Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/21
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactionsPRNewsWire • 07/07/21
Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards INDBusiness Wire • 06/29/21
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAMEGlobeNewsWire • 05/11/21